Zydus Lifesciences Launches ANVIMO, a Breakthrough for Transplant Patients in India at 91% Lower Cost

Zydus Lifesciences, a leading global lifesciences company, has announced the launch of ANVIMO (Letermovir), a breakthrough in the prevention of Cytomegalovirus (CMV) infection for haematopoietic stem cell transplant (HSCT) and kidney transplant patients. ANVIMO will be available in dosages of 240 mg and 480 mg. The launch of ANVIMO significantly reduces the cost by 91% of the innovator price, making treatment of CMV prophylaxis significantly more affordable for Indian patients. ANVIMO has established bioequivalence with the reference drug, ensuring quality at a fraction of the cost. The introduction of ANVIMO marks a new era in bone marrow transplant and kidney transplant care in India, improving survival rates and quality of life for transplant patients.